Monday, March 25, 2013

Heart repair breakthroughs replace surgeon’s knife | The Daily Star

Heart repair breakthroughs replace surgeon’s knife | The Daily Star:

MONDAY, MARCH 25, 2013


Heart repair breakthroughs replace surgeon’s knife


    



Atlanta cardiologist Dr Spencer King demonstrates how a catheter is used to repair a diseased heart valve, at an American College of Cardiology conference in San Francisco on Monday. Photo: AP
Atlanta cardiologist Dr Spencer King demonstrates how a catheter is used to repair a diseased heart valve, at an American College of Cardiology conference in San Francisco on Monday. Photo: AP
Have a heart problem? If it’s fixable, there’s a good chance it can be done without surgery, using tiny tools and devices that are pushed through tubes into blood vessels.
Heart care is in the midst of a transformation. Many problems that once required sawing through the breastbone and opening up the chest for open heart surgery now can be treated with a nip, twist or patch through a tube.
These minimal procedures used to be done just to unclog arteries and correct less common heart rhythm problems. Now some patients are getting such repairs for valves, irregular heartbeats, holes in the heart and other defects – without major surgery. Doctors even are testing ways to treat high blood pressure with some of these new approaches.
All rely on catheters – hollow tubes that let doctors burn away and reshape heart tissue or correct defects through small holes in blood vessels.
“This is the replacement for the surgeon’s knife. Instead of opening the chest, we’re able to put catheters in through the leg, sometimes through the arm,” said Dr Spencer King of St Joseph’s Heart and Vascular Institute in Atlanta. He is former president of the American College of Cardiology. Its conference earlier this month featured research on these novel devices.
“Many patients after having this kind of procedure in a day or two can go home” rather than staying in the hospital while a big wound heals, he said. It may lead to cheaper treatment, although the initial cost of the novel devices often offsets the savings from shorter hospital stays.
Not everyone can have catheter treatment, and some promising devices have hit snags in testing. Others on the market now are so new that it will take several years to see if their results last as long as the benefits from surgery do.
But already, these procedures have allowed many people too old or frail for an operation to get help for problems that otherwise would likely kill them.
“You can do these on 90-year-old patients,” King said.
These methods also offer an option for people who cannot tolerate long-term use of blood thinners or other drugs to manage their conditions, or who don’t get enough help from these medicines and are getting worse.
“It’s opened up a whole new field,” said Dr Hadley Wilson, cardiology chief at Carolinas HealthCare System in Charlotte. “We can hopefully treat more patients more definitively, with better results.”
For patients, this is crucial: Make sure you are evaluated by a “heart team” that includes a surgeon as well as other specialists who do less invasive treatments. Many patients now get whatever treatment is offered by whatever specialist they are sent to, and those specialists sometimes are rivals.
“We want to get away from that” and do whatever is best for the patient, said Dr Timothy Gardner, a surgeon at Christiana Care Health System in Newark, Del, and an American Heart Association spokesman. “There shouldn’t be a rivalry in the field.”
Here are some common problems and newer treatments for them:
HEART VALVES
Millions of people have leaky heart valves. Each year, more than 100,000 people in the United States alone have surgery for them. A common one is the aortic valve, the heart’s main gate. It can stiffen and narrow, making the heart strain to push blood through it. Without a valve replacement operation, half of these patients die within two years, yet many are too weak to have one.
“Essentially, this was a death sentence,” said Dr John Harold, a Los Angeles heart specialist who is president of the College of Cardiology.
That changed just over a year ago, when Edwards Lifesciences Corp won approval to sell an artificial aortic valve flexible and small enough to fit into a catheter and wedged inside the bad one. At first it was just for inoperable patients. Last fall, use was expanded to include people able to have surgery but at high risk of complications.
Gary Verwer, 76, of Napa, Calif, had a bypass operation in 1988 that made surgery too risky when he later developed trouble with his aortic valve.
“It was getting worse every day. I couldn’t walk from my bed to my bathroom without having to sit down and rest,” he said. After getting a new valve through a catheter last April at Stanford University, “everything changed; it was almost immediate,” he said. “Now I can walk almost three miles a day and enjoy it. I’m not tired at all.”
“The chest cracking part is not the most fun,” he said of his earlier bypass surgery. “It was a great relief not to have to go through that recovery again.”
Catheter-based treatments for other valves also are in testing. One for the mitral valve – Abbott Laboratories’ MitraClip – had a mixed review by federal Food and Drug Administration advisers this week; whether it will win FDA approval is unclear. It is already sold in Europe.
HEART RHYTHM PROBLEMS
Catheters can contain tools to vaporize or “ablate” bits of heart tissue that cause abnormal signals that control the heartbeat. This used to be done only for some serious or relatively rare problems, or surgically if a patient was having an operation for another heart issue.
Now catheter ablation is being used for the most common rhythm problem – atrial fibrillation, which plagues about 3 million Americans and 15 million people worldwide. The upper chambers of the heart quiver or beat too fast or too slow. That lets blood pool in a small pouch off one of these chambers. Clots can form in the pouch and travel to the brain, causing a stroke.
Ablation addresses the underlying rhythm problem. To address the stroke risk from pooled blood, several novel devices aim to plug or seal off the pouch. Only one has approval in the US now – SentreHeart Inc.’s Lariat, a tiny lasso to cinch the pouch shut. It uses two catheters that act like chopsticks. One goes through a blood vessel and into the pouch to help guide placement of the device, which is contained in a second catheter poked under the ribs to the outside of the heart. A loop is released to circle the top of the pouch where it meets the heart, sealing off the pouch.
A different kind of device – Boston Scientific Corp’s Watchman – is sold in Europe and parts of Asia, but is pending before the FDA in the US It’s like a tiny umbrella pushed through a vein and then opened inside the heart to plug the troublesome pouch. Early results from a pivotal study released by the company suggested it would miss a key goal, making its future in the US uncertain.
HEART DEFECTS
Some people have a hole in a heart wall called an atrial septal defect that causes abnormal blood flow. St Jude Medical Inc.’s Amplatzer is a fabric-mesh patch threaded through catheters to plug the hole.
The patch is also being tested for a more common defect – PFO, a hole that results when the heart wall doesn’t seal the way it should after birth. This can raise the risk of stroke. In two new studies, the device did not meet the main goal of lowering the risk of repeat strokes in people who had already suffered one, but some doctors were encouraged by other results.
CLOGGED ARTERIES
The original catheter-based treatment – balloon angioplasty – is still used hundreds of thousands of times each year in the US alone. A Japanese company, Terumo Corp., is one of the leaders of a new way to do it that is easier on patients – through a catheter in the arm rather than the groin.
Newer stents that prop arteries open and then dissolve over time, aimed at reducing the risk of blood clots, also are in late-stage testing.
HIGH BLOOD PRESSURE
About 75 million Americans and 1 billion people worldwide have high blood pressure, a major risk factor for heart attacks. Researchers are testing a possible long-term fix for dangerously high pressure that can’t be controlled with multiple medications.
It uses a catheter and radio waves to zap nerves, located near the kidneys, which fuel high blood pressure. At least one device is approved in Europe and several companies are testing devices in the United States.
“We’re very excited about this,” said Harold, the cardiology college’s president. It offers hope to “essentially cure high blood pressure.”

'via Blog this'

Tuesday, March 5, 2013

LED Lighting to Grow 40% in 2013, Philips Executive Says - Bloomberg

LED Lighting to Grow 40% in 2013, Philips Executive Says - Bloomberg:

LED Lighting to Grow 40% in 2013, Philips Executive Says

Royal Philips Electronics NV (PHIA)’s light-emitting diodes business will grow about 40 percent this year, Greg Sebasky, chief executive officer of it North America unit, said today in an interview.
The company sees a “growth tipping point” with the debut this year of its 60-watt equivalent LED light bulb that will retail for about $10, Sebasky said. That will help the energy- efficient technology make up about 50 percent of Philips’ lighting sales by 2015, up from 25 percent last year, he said.
The company sees a “growth tipping point” with the debut this year of its 60-watt equivalent LED light bulb that will retail for about $10, Sebasky said. Photographer: Mark Elias/Bloomberg
“People are starting to see lighting as a durable good,” Sebasky said, taking lighting products with them when they move. The company is making controllable, LED-driven lighting products that the company expects can save the average homeowner about $250 in electricity costs each year.
The unit of the Dutch electronics company Koninklijke Philips Electronics NV generates about $9 billion in annual sales in the U.S., Canada and Mexico.
To contact the reporter on this story: Ehren Goossens in New York at egoossens1@bloomberg.net
To contact the editor responsible for this story: Reed Landberg at landberg@bloomberg.net

'via Blog this'

Friday, February 1, 2013

10 Indian-Americans among 40 Intel science finalists - Rediff Getahead

10 Indian-Americans among 40 Intel science finalists - Rediff Getahead:

10 Indian-Americans among 40 Intel science finalists

Last updated on: February 1, 2013 15:55 IST
Lalit K Jha, Courtesy PTI
The finalists will present their research findings across 16 branches of science between March 7 and 13 this year.
Ten Indian-American school students have made it to the 40 finalists of the prestigious Intel Science Talent Search for the year 2013.
These 40 students were selected from 300 semi-finalists and more than 1,700 entrants to compete in Washington, DC from March 7 to 13 for USD 630,000 in awards, with the top winner receiving USD 100,000 from the Intel Foundation.
The 10 Indian-American students include the maximum three from California -- Paulomi Bhattacharya from Cupertino, Pavan Mehrotra from Simi Valley and Sahana Vasudevan from Palo Alto.
Two Indian-Americans are from Portland in Oregon -- Naomi Shah and Raghav Tripathi.
The other five are Surya Bhupatiraju from Lexington in Massachusetts, Naethan Mundukur from Louisville in Kentucky, Akshay Padmanabha from Collierville in Tennessee, Raja Selvakumar from Alpharetta in Georgia, and Mayuri Sridhar from Kings Park in New York.
"This year's Intel Science Talent Search finalists are presenting a wide range of research, from optimising algae oil for biofuel to developing a new treatment for blood cancer," said Wendy Hawkins, executive director of the Intel Foundation.
"It's exciting for the future of innovation because the US needs these 40 high school seniors, and others like them, to question, explore and help solve some of the world's greatest challenges," Hawkins said.
Young innovators chosen to participate in the Science Talent Search over the past 72 years have gone on to receive some of the world's most prestigious honours.
For example, Science Talent Search alumni have gone on to win seven Nobel Prizes, two Fields Medals, five National Medals of Science, 11 MacArthur Foundation Fellowships and even an Academy Award for Best Actress.
The finalists are from 40 schools in 21 states. Among the finalists, there is an equal gender distribution with both 50 per cent males and females.
California and New York represent over 30 per cent of this year's finalists.
Finalist projects are distributed among 16 categories, including bioengineering, chemistry, mathematics, computer science, physics and space science, behavioural and social sciences, and plant science.


'via Blog this'

Monday, January 7, 2013

The Future of Medicine Is Now: Medical Innovations - WSJ.com

The Future of Medicine Is Now: Medical Innovations - WSJ.com:

Reporter Ron Winslow talks to WSJ weekend Review editor Gary Rosen about astonishing medical advances that are finally moving from research and prototypes to practical treatments.

In our era of instant gratification, the world of medicine seems like an outlier. The path from a promising discovery to an effective treatment often takes a decade or more.

But from that process—of fits and starts, progress and setbacks and finally more progress—grow the insights and advances that change the course of medicine.

A decade ago, the completion of the Human Genome Project sparked optimism that cures for debilitating diseases were just around the corner. Cures still generally elude us, but now the ability to map human DNA cheaply and quickly is yielding a torrent of data about the genetic drivers of disease—and a steady stream of patients who are benefiting from the knowledge. On other fronts, technology is putting more power in the hands of patients, and researchers are learning to combat disorders by harnessing the body's own ability to heal and grow.
Foundation Medicine
A test developed by Foundation Medicine Inc. analyzes tumor DNA to help find targeted treatment options for patients with cancer.

Advances bring other challenges, including how to pay for them. Meanwhile, the complex biology that stymies gains for some patients sets goals for new advances.

Here are six of today's potentially transformative trends.
Growing a Heart

Surgeons at Boston Children's Hospital have developed a way to help children born with half a heart to essentially grow a whole one—by marshaling the body's natural capacity to heal and develop.

About 1,000 babies are born in the U.S. each year with a condition called hypoplastic left-heart syndrome, the result of a genetic anomaly that leaves them without a functioning left ventricle, the heart's main pumping chamber. Without a surgical repair, the defect is almost always fatal.
Jennifer S. Altman for The Wall Street Journal
A new surgical strategy helped 9-year-old Alexa Rand's body to essentially grow half a heart into a whole one.

The standard treatment is a series of three open-heart operations to reroute circulation so that the right ventricle can take over pumping blood to the body's organs and extremities. But the right ventricle "is meant to handle low-pressure blood flow to the lungs," says Sitaram Emani, the surgeon heading the effort on the new approach. "Now you're asking it to do the work of a high-pressure system and to do that work for many years. Eventually it fails." That's one reason why 30% of patients or more don't survive to adulthood.

Dr. Emani and his colleagues devised a complex strategy to open obstructed valves and repair other malformations to direct blood flow to the left ventricle instead of away from it. That triggers biological processes that promote the heart's growth.

Last month, after using the approach on 34 carefully selected patients over the past decade, the doctors reported in the Journal of the American College of Cardiology that 12 now have two working ventricles. One of them, 9-year-old Alexa Rand of Kings Park, N.Y., whose treatments began in utero, is thriving. She sings, dances and surprises doctors with how long she can walk on a treadmill, says her mother, Rosamaria Rand.

The main drawback: The strategy requires one more surgical procedure, on average, and significantly more days in the hospital than the conventional surgery. The hope is, Dr. Emani says, that the long-term benefits will outweigh the extra hospital time.
—Ron Winslow
DNA Sequencing for Routine Checkups

At a genetics conference in November, Oxford Nanopore Technologies unveiled the first of a generation of tiny DNA sequencing devices that many predict will eventually be as ubiquitous as cellphones—it's already the size of one.

Since the first sequencing of the human genome was completed in 2003 at a price tag of over $2 billion, the speed, price and accuracy of the technology have all improved. Illumina Inc. ILMN -7.06% has dropped its price for individual readouts to $5,000; earlier this year, Life Technologies introduced a sequencer it says can map the human genome for $1,000. The smallest machine is now desktop-size.

But nanopore sequencing devices, which are designed to be even smaller and more affordable, could speed efforts to make gene sequencing a routine part of a visit to the doctor's office. DNA molecules are exceedingly long and complicated; that makes them hard to read. Nanopore technology measures changes in the molecules' electrical current as the DNA is threaded in a single strand through tiny holes called "nanopores" created in a membrane.

So far, U.K.-based Oxford has released the results of sequencing a virus genome with this technique. The company hasn't provided data, however, showing that the sequencers can analyze the much larger human genome. A spokeswoman for Oxford says the company is working hard toward being able to sell devices, including one that is expected to cost under $1,000, though it doesn't yet have a launch date.

Amit Meller—an associate professor at Boston University, a scientific adviser at Oxford and the co-founder of Noblegen Biosciences—is at work on another nanopore device that he says would use fluorescent signals to read the DNA information. His company is still a number of years away from a prototype, but Dr. Meller says the goal is to speed up sequencing even more—with results in a few hours, not the current weeks or days, at a cost of less than $100.
—Amy Dockser Marcus
Matching a Tumor to a Drug

Our growing understanding of the workings of the human genome is posing a new challenge: How to use that data to change the course of disease. Consider cancer. As seen through a gene-sequencing machine, some cancers can appear as at least a dozen different genetic diseases, some of which have been shown to respond uniquely to a specific drug. But how do cancer doctors quickly match a patient's tumor with a drug that targets it?

One answer is a test developed by Foundation Medicine Inc., a Cambridge, Mass., startup whose scientific founders include one of the leaders of the Human Genome Project. The test, officially launched last June, enables doctors to test a tumor sample for 280 different genetic mutations suspected of driving tumor growth.

This changes "everything in terms of how we approach patients with cancer," says David Spigel, director of lung-cancer research at the Sarah Cannon Research Institute in Nashville, Tenn. He used the test in one patient with advanced disease and few apparent options. She turned out positive for an alteration in a gene targeted by several drugs currently in development. She was signed up for one of the studies. A short time later, "she's like a new person," he says. "She's off pain medicines. She gained her weight back."

Michael Pellini, Foundation's chief executive officer, says that more than 600 oncologists have requested the test, which lists for $5,800. So far, he says, about 70% of cases have turned up a mutation that is potentially targeted by a drug on the market or in a clinical trial.

In one recent case, Dr. Pellini says, a sample from a woman with advanced pancreatic cancer yielded a response for "her2," an alteration associated with a certain form of breast cancer. She was treated and her cancer responded to the breast-cancer drug Herceptin. Few oncologists would think to look for her2 in a patient with pancreatic cancer, he says.
—Ron Winslow
Letting Your Body Fight Cancer

Few advances in cancer care are generating more enthusiasm than harnessing the power of the immune system to fight the disease.

Tom Stutz is one reason why. Last April, the 72-year-old retired lawyer was confined to a wheelchair, struggling for every breath, and required help with simple tasks such as eating, all because of a previously diagnosed skin cancer that had spread to his lungs and liver. "I was ready to check out, to be honest," he says.

That month, he began taking an experimental drug known as MK3475. Six weeks later, he started feeling better. Today, Mr. Stutz has jettisoned the wheelchair and regularly walks a 3.5-mile loop near his home in Los Angeles. "I feel terrific," says Mr. Stutz, who learned after a checkup in the fall that his tumors had shrunk by about 65% so far.

For decades, cancer researchers have wondered why the immune system typically doesn't treat tumor cells as invaders and target them. Part of the mystery was recently solved: Tumors protect themselves by hijacking the body's natural brake for the immune system.

MK3475, being developed by Merck & Co., is among a new category of drugs that release the brake, unleashing an army of immune cells to hunt down the cancer. A recent report from a trial in which Mr. Stutz participated said that of 85 patients who took the drug, 51% saw their tumors significantly shrink; in eight cases, the tumors couldn't be detected on imaging tests.

Still, not everyone was helped. And unleashing the immune system can put normal cells in harm's way: In studies of MK3745 and similar drugs, some patients developed serious side effects related to immune-system response, including a small number who died.

But interest in the approach is strong. Bristol-Myers Squibb Corp.'s BMY +0.15%drug Yervoy, approved by the Food and Drug Administration in 2011, is the first of its kind to reach the market. The company has others in development. GlaxoSmithKlineGSK.LN -0.69% PLC and AstraZeneca's AZN.LN -0.50% MedImmune are among others exploring ways to activate the immune system against cancer.

One reason for the excitement is that most "solid" tumors—colon, lung, breast, prostate—use the same or a similar mechanism to hide from the immune system. Obstructing that mechanism may have a broad impact across a variety of malignancies.
—Ron Winslow
Health in the Palm of Your Hand

There's a good chance that you already own one of the most ubiquitous health-care innovations: a smartphone. Last month, the FDA cleared a new iPhone add-on that lets doctors take an electrocardiogram just about anywhere. Other smartphone apps help radiologists read medical images and allow patients to track moles for signs of skin cancer.

"I see the smartphone as one piece of how we're going to try to get health costs under control," says David Albert, the Oklahoma City-based inventor of the just-approved AliveCor electrocardiogram application.

At $199, AliveCor consists of a case that snaps onto the iPhone, with electrodes on the back. It reads heart rhythms and relays the recording to an iPhone app, allowing physicians to read the data. Dr. Albert says a $99 version should be available soon that will let patients capture their own heart data, documenting sometimes-fleeting arrhythmias when they feel symptoms or tracking the success of lifestyle changes at curbing heart troubles.

Doctors say that mainstream EKG machines provide more information but the iPhone version is sufficient for many diagnostic needs. "When I go to [the] clinic, I use it in place of an EKG all the time," says Leslie Saxon, chief of the University of Southern California's heart-rhythm department, which has conducted research using AliveCor's device.

The FDA has cleared a handful of apps, beginning with an iPad- and iPhone-based medical imaging reader in 2011. The smartphone lets us "bring health care into the home," says Erik Douglas, CEO of CellScope. His company is developing an iPhone-based otoscope that would allow parents to upload images of the inside of children's ears when they show signs of infections, with the aim of avoiding unnecessary doctors visits.
—Christopher Weaver
Rejigging Your Genes

After years of controversy, gene therapy is poised to become a viable option for a variety of often life-threatening medical conditions, especially those resulting from a single defective gene. Last month, the European Union approved Glybera for treatment of a rare genetic disease, making it the first gene-therapy medicine approved in the Western world. The approval comes amid a flurry of research showing broader promise for the approach in a range of disorders, from a rare form of blindness to hemophilia to heart failure.

Though outright cures are still elusive, gene therapy "is beginning to emerge as a meaningful clinical" strategy, says Stephen J. Russell, director of molecular medicine at the Mayo Clinic in Rochester, Minn.

Gene therapy's tantalizing attraction is that a single treatment has the potential to cure lethal diseases by enabling normal genes to take over for defective ones. The treatment involves loading a functional gene onto a fragment of a deactivated virus that transports the gene to a cell's nucleus, where it is intended to take over.

The idea suffered major setbacks in 1999 when a U.S. teenager died in a gene-therapy trial and again soon after when several children in Europe developed leukemia after receiving gene therapy.

The episodes prompted criticism that researchers had moved too quickly. Scientists returned to the laboratory, hoping to develop better delivery vehicles and to improve both the safety and efficacy of the treatments.

Bluebird Bio, a Cambridge, Mass., gene-therapy startup, expects to launch studies next year for two rare genetic diseases: childhood adrenoleukodystrophy, or ALD, an inherited and lethal neurological disorder; and beta thallasemia, which causes the destruction of red blood cells and leads to life-threatening anemia. Its technique involves extracting a patient's own bone-marrow cells, isolating certain stem cells, and delivering the gene therapy before returning the cells to the body.

Four boys in Paris with ALD have been successfully treated, says Nick Leschly, Bluebird's president and chief executive officer, including two treated nearly six years ago. They are now in their teens and would otherwise likely have died before age 10, he says.

Other gene-therapy efforts include Novartis SA's NOVN.VX -0.34% partnership with the University of Pennsylvania on a treatment for cancer, GlaxoSmithKline's alliance with Italian scientists for a range of disorders, and Celedon Corp.'s clinical trial of a gene therapy in patients with advanced heart failure.
—Ron Winslow
Corrections & Amplifications
CellScope's iPad- and iPhone-based otoscope records images of the inside of children's ears. An earlier version of this article incorrectly said it captured the inner ear.
A version of this article appeared December 29, 2012, on page C2 in the U.S. edition of The Wall Street Journal, with the headline: No Headline Available.

'via Blog this'